Lv2
170 积分 2021-06-10 加入
IUPHAR review: Navigating the role of preclinical models in pain research
1天前
已完结
Drug discovery targeting Nav1.8: Structural insights and therapeutic potential
30天前
已完结
Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses
2个月前
已完结
Discovery of a novel GPR35 agonist with high and equipotent species potency for oral treatment of IBD
2个月前
已完结
IDDF2022-ABS-0053 GPR35 deficiency induces GUT microbial reconfiguration to increase colitis susceptibility
2个月前
已完结
GPR35: from enigma to therapeutic target
2个月前
已完结
Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain
2个月前
已完结
Efficacy and safety of eliapixant in diabetic neuropathic pain and prediction of placebo responders with an exploratory novel algorithm: results from the randomized controlled phase 2a PUCCINI study
10个月前
已完结
Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study
10个月前
已完结
Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers
11个月前
已完结
皖公网安备34019202002308
